Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsTransplantation is the optimal option for patients with end-stage organ failure, but this may cause varying degrees of immune rejection in patients. Antibody therapy, on the other hand, can alleviate the damage caused by immune rejection to some extent. As antibody-based therapy for immune rejection continues to be researched, antibodies have evolved from anti-thymocyte globulin antibodies to anti-CD3 positive clones and anti-CD20, CD25, and CD52 antibodies. Creative Biolabs offers comprehensive services to support the development of allograft rejection-specific target antibodies. Based on our hybridoma platform and phage display platform, we can provide you with high-quality and efficient custom antibody production services.
The use of polyclonal or monoclonal antibodies or relatively high doses of conventional immunosuppression are two ways to implement induction therapy strategies, of which the ultimate goal is to benefit high-risk populations, particularly children, recipients with human leukocyte antigen mismatches, or those sensitive to these antigens. In addition, induction therapy is designed to reduce the risk of acute rejection and maintenance immunosuppression regimens. The goal of antibody therapy is enhancing immunosuppression, ensuring that delayed introduction of calcium-regulated phosphatase inhibitors is safe, encouraging steroid withdrawal, and facilitating treatment of patients sensitive to human leukocyte antigens. It also plays a key role in immune preconditioning by causing tolerance or using less immunosuppressive drugs.
Anti-thymocyte globulin is a polyclonal IgG fraction prepared from the sera of rabbit, horse, goat, or pig, which have been immunized against human or other lymphocytes. Antithymocyte globulin plays an important role both in the prevention of graft-versus-host disease and in the treatment of refractory graft-versus-host disease. Antithymocyte globulin is commonly used as part of pre-treatment before hematopoietic stem cell transplantation to prevent graft-versus-host disease and may also increase the risk of infection due to T-cell depletion. In some cases, the risk of disease recurrence may be increased due to a diminished graft-versus-leukemia effect. Studies have shown that anti-thymocyte globulin may reduce the risk of graft rejection in the presence of reduced pretreatment intensity. In hormone-refractory acute graft-versus-host disease, antithymocyte globulin is among the standard treatments, especially in patients with full-blown multi-organ acute GVHD who are not receiving prophylactic ATG.
The CD3 molecule is a complex molecule composed of peptide chains bonded in a non-covalent way and expressed on the surface of mature T cells. It forms the TCR–CD3 complex with the T cell receptor (TCR) and has an important role in T cell antigen recognition and immune response generation. The roles of CD3 molecules in stabilizing TCR structure and transmitting activation signals enable anti-CD3 monoclonal antibodies the ability to stimulate or block T cell activation signal transduction, which, in turn, can clear effector T cells or induce the production of regulatory T cells. The mechanism provides a new idea for the treatment of organ transplant rejection and autoimmune diseases.
Anti-allograft-rejection-specific target antibodies have been shown to have a significant therapeutic effect on immune rejection in organ transplantation. Based on our extensive hands-on experience, Creative Biolabs is pleased to share our knowledge and experience with anti-allograft-rejection-specific target antibodies to help your study proceed smoothly.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
